Regeneron (REGN), Bayer Report EYLEA Achieved Primary Endpoint in Phase 3s

August 6, 2013 6:50 AM

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare today announced that in the Phase 3 VIVID-DME and VISTA-DME trials of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found